William Shrader, PhD, has 26 years of experience in the pharmaceutical industry. During the last 14 years, he has led teams that have advanced 3 drugs into the clinic for neurodegenerative diseases. These drugs have completed phase 2 clinical trials in Parkinson’s disease, amyotrophic lateral sclerosis (ALS), Friedriech’s ataxia, Rett Syndrome, and Leigh syndrome. Dr. Shrader has also successfully led a team for the development of clinical biomarkers for a Phase 2 ALS trial, demonstrating target engagement.
Dr. Shrader earned his doctorate in organic chemistry at the University of California, Berkeley and completed a post-doctoral fellowship at Caltech.